WWW.JNEUROSCI.ORG
-
The Journal of Neuroscience behavioral testing systems
 QUICK SEARCH:   [advanced]


     
-


HOME
  |  
SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

The Journal of Neuroscience, October 13, 2004, 24(41):9117-9126; doi:10.1523/JNEUROSCI.2729-04.2004

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit an eLetter
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via ISI Web of Science (25)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sleat, D. E.
Right arrow Articles by Lobel, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sleat, D. E.
Right arrow Articles by Lobel, P.

 Previous Article  |  Next Article 

Neurobiology of Disease
A Mouse Model of Classical Late-Infantile Neuronal Ceroid Lipofuscinosis Based on Targeted Disruption of the CLN2 Gene Results in a Loss of Tripeptidyl-Peptidase I Activity and Progressive Neurodegeneration

David E. Sleat,1,2 Jennifer A. Wiseman,1 Mukarram El-Banna,1 Kwi-Hye Kim,1 Qinwen Mao,4 Sandy Price,1 Shannon L. Macauley,5 Richard L. Sidman,6 Michael M. Shen,1,3 Qi Zhao,5 Marco A. Passini,5 Beverly L. Davidson,4 Gregory R. Stewart,5 and Peter Lobel1,2

1Center for Advanced Biotechnology and Medicine, and Departments of 2Pharmacology and 3Pediatrics, University of Medicine and Dentistry of New Jersey, Piscataway, New Jersey 08854, 4Department of Internal Medicine, University of Iowa College of Medicine, Iowa City, Iowa 52242, 5Genzyme Corporation, Framingham, Massachusetts 01701, and 6Department of Neurology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02115

Mutations in the CLN2 gene, which encodes a lysosomal serine protease, tripeptidyl-peptidase I (TPP I), result in an autosomal recessive neurodegenerative disease of children, classical late-infantile neuronal ceroid lipofuscinosis (cLINCL). cLINCL is inevitably fatal, and there currently exists no cure or effective treatment. In this report, we provide the characterization of the first CLN2-targeted mouse model for cLINCL. CLN2-targeted mice were fertile and apparently healthy at birth despite an absence of detectable TPP I activity. At ~7 weeks of age, neurological deficiencies became evident with the onset of a tremor that became progressively more severe and was eventually accompanied by ataxia. Lifespan of the affected mice was greatly reduced (median survival, 138 d), and extensive neuronal pathology was observed including a prominent accumulation of cytoplasmic storage material within the lysosomal-endosomal compartment, a loss of cerebellar Purkinje cells, and widespread axonal degeneration. The CLN2-targeted mouse therefore recapitulates much of the pathology and clinical features of cLINCL and represents an animal model that should provide clues to the normal cellular function of TPP I and the pathogenic processes that underlie neuronal death in its absence. In addition, the CLN2-targeted mouse also represents a valuable model for the evaluation of different therapeutic strategies.

Key words: cerebellum; degeneration; enzyme; epilepsy; lysosome; neuropathology; proteolysis


Received May 19, 2004; revised August 3, 2004; accepted August 3, 2004.






-

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help

-
Copyright 2008 by Society for Neuroscience ONLINE ISSN: 1529-2401
-